)
)
)
Nasus Pharma
Company Description: Nasus Pharma vision is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly, safe and immediately active powder-based Intranasal specialized products.
Nasus pharma brings the new frontier in Intranasal drug delivery. Late-Stage Specialty Pharma company, offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats.
Nasax® – proprietary powder formulation for intranasal delivery comprised of uniform spherical API and a carrier approved for inhalation. Technology aims for a rapid and precise delivery of the drug to the bloodstream and brain. Stability data demonstrated potential for longer shelf life.
Goal for Presentation: Seeking Investment Seeking out-licensing opportunities Seeking R&D Collaboration/Partnership
Additional Comments:
Who referred you to this application?: Bio Org Customer Service
Goal for Presentation: Seeking Investment Seeking out-licensing opportunities Seeking R&D Collaboration/Partnership
Additional Comments:
Who referred you to this application?: Bio Org Customer Service
Year Founded
2019
Lead Product in Development
IP-001 is a cationic polymer designed to utilize antigens/tumor debris liberated from approved, traditional interventional oncology procedures (such as tumor ablation) or other methodologies of tumor destruction like radiation therapy, transforming such routine tumor-destruction techniques into a systemic immunotherapy.
Development Phase of Lead Product
Phase II
Exchange
NYSE: American
Ticker
NSRX
CEO/Top Company Official
Dan Teleman
When you expect your next catalyst update?
Next major inflection point anticipated in January 2028.
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
